Thomas Jefferson University

Jefferson Digital Commons
Division of Gastroenterology and Hepatology
Faculty Papers

Division of Gastroenterology and Hepatology

9-2013

Occupational exposure to hepatitis C virus: early T-cell responses
in the absence of seroconversion in a longitudinal cohort study.
Theo Heller
National Institutes of Health

Jens Martin Werner
National Institutes of Health

Fareed Rahman
National Institutes of Health

Eishiro Mizukoshi
National
Institutes
of Health
Follow this
and additional
works at: https://jdc.jefferson.edu/gastro_hepfp
of the Gastroenterology Commons
YujiPart
Sobao

Let us know how access to this document benefits you
National Institutes of Health

Recommended
See
next page forCitation
additional authors
Heller, Theo; Werner, Jens Martin; Rahman, Fareed; Mizukoshi, Eishiro; Sobao, Yuji; Gordon, Ann
Marie; Sheets, Arlene; Sherker, Averell H.; Kessler, Ellen; Bean, Kathleen S.; Herrine, Steven K.;
Stevens, M'lou; Schmitt, James; and Rehermann, Barbara, "Occupational exposure to hepatitis C
virus: early T-cell responses in the absence of seroconversion in a longitudinal cohort study."
(2013). Division of Gastroenterology and Hepatology Faculty Papers. Paper 80.
https://jdc.jefferson.edu/gastro_hepfp/80
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Division of Gastroenterology and Hepatology Faculty Papers by an authorized
administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.

Authors
Theo Heller, Jens Martin Werner, Fareed Rahman, Eishiro Mizukoshi, Yuji Sobao, Ann Marie Gordon, Arlene
Sheets, Averell H. Sherker, Ellen Kessler, Kathleen S. Bean, Steven K. Herrine, M'lou Stevens, James
Schmitt, and Barbara Rehermann

This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/gastro_hepfp/80

MAJOR ARTICLE

Theo Heller,1 Jens Martin Werner,1 Fareed Rahman,1 Eishiro Mizukoshi,1 Yuji Sobao,1 Ann Marie Gordon,2
Arlene Sheets,2 Averell H. Sherker,3,a Ellen Kessler,4 Kathleen S. Bean,4 Steven K. Herrine,5 M’Lou Stevens,6
James Schmitt,6 and Barbara Rehermann1
1
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human
Services, Bethesda, Maryland; 2Occupational Health, Medstar Washington Hospital Center, 3Center for Liver Diseases, Medstar Washington Hospital
Center, Washington, DC; 4Employee Occupational Health, Inova Fairfax Hospital, Falls Church, Virginia; 5Thomas Jefferson University, Philadelphia,
Pennsylvania; and 6Occupational Medical Service, National Institutes of Health, Department of Health and Human Services, Bethesda Maryland

Background. T-cell responses have been described in seronegative patients who test negative for hepatitis C
virus (HCV) RNA despite frequent HCV exposure. However, the cross-sectional design of those studies did not
clarify whether T cells were indeed induced by low-level HCV exposure without seroconversion or whether they resulted from regular acute infection with subsequent antibody loss.
Methods. Over a 10-year period, our longitudinal study recruited 72 healthcare workers with documented
HCV exposure. We studied viremia and antibody and T-cell responses longitudinally for 6 months.
Results. All healthcare workers remained negative for HCV RNA and antibodies. However, 48% developed
proliferative T-cell response and 42% developed responses in interferon-gamma enzyme-linked immunosorbent
spot assays, with 29 healthy HCV-unexposed controls used to deﬁne assay cutoffs. The response prevalence was
associated with the transmission risk score. T-cell responses peaked at week 4 and returned to baseline by week 12
after exposure. They predominantly targeted nonstructural HCV proteins, which are not part of the HCV particle
and thus must have been synthesized in infected cells.
Conclusions. Subclinical transmission of HCV occurs frequently, resulting in infection and synthesis of nonstructural proteins despite undetectable systemic viremia. T-cell responses are more sensitive indicators of this lowlevel HCV exposure than antibodies.
Keywords. exposure; needlestick; antibody; T cell; hepatitis; healthcare worker.
Hepatitis C virus (HCV) infection constitutes a serious
global health problem, with more than 120 million
people chronically infected. Since the introduction of
blood donor screening in the early 1990s, the epidemiology of HCV infection has changed. In the United
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States, transmission via blood transfusion is now effectively prevented via donor screening [1], and most
cases of infection occur in injection drug users via
HCV-contaminated needles [2, 3]. In addition, healthcare workers are at risk of infection due to sharp injuries.
Some of the largest studies on virus exposure in
healthcare workers were conducted by the Centers for
Disease Control and Prevention Needlestick Surveillance Group as multicenter case-control studies. In
those studies, healthcare workers who developed antibodies to either HCV [4] or human immunodeﬁciency
virus (HIV) [5] were classiﬁed as cases, whereas those
who did not seroconvert were classiﬁed as controls.
Likewise, a large surveillance study in Europe followed
245 healthcare workers for 5 years using seroconversion
as evidence of exposure [6].
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Occupational Exposure to Hepatitis C Virus:
Early T-Cell Responses in the Absence of
Seroconversion in a Longitudinal Cohort Study

Table 1.

Characteristics of the Studied Healthcare Workers

Characteristic

n (%)

Subjects

72

Male

30 (41.6)

Type of Exposure
Needlestick/Cut

54 (75)

Risk score, lowa

16 (22.2)

Risk score, medium
Risk score, high

25 (30.6)
13 (18.1)

Cutaneous
Mucosal
Serum HCV RNAb
HCV antibodiesc

7 (9.7)
11 (15.3)
0 (0)
0 (0)

Abbreviation: HCV, hepatitis C virus.
a

Risk score for HCV transmission as described in the Materials and Methods
section.

b

Determined by qualitative reverse-transcription polymerase chain reaction
(COBAS Amplicor HCV Test 2.0) at all study time points.

of low-dose HCV exposure than antibodies, which is relevant
for surveillance studies and for vaccine development.
METHODS
Study Cohort

Seventy-two healthcare workers with documented HCV exposure were followed prospectively at the National Institutes of
Health (NIH; n = 31), Washington Hospital Center (n = 27),
and Inova Fairfax Hospital (n = 14; Table 1). All gave written
informed consent for research testing according to protocols
approved by the participating hospitals’ institutional review
boards (ClinicalTrials.gov NCT00006301). Needlestick injuries
were assigned a transmission risk score of “low” (0–1 points),
“medium” (2–3 points), or “high” (4–5 points) that we derived
from epidemiologic studies on HIV and HCV transmission [5,
21]. This score was based on the transmission route (1 point,
transmission from a blood vessel, ie, the needle had been inserted into a patient’s blood vessel prior to the accidental needlestick; 0 points, no transmission from a blood vessel), exposure
type (1 point, fresh blood; 0 points, old blood), depth of injury
(1 point, deep; 0 points, superﬁcial), and the needle itself
(2 points, hollow-bore >18G; 1 point, hollow-bore <18G; 0
points, solid).
Study time points for clinical visits and analysis of HCV
RNA (Cobas Amplicor, HCV Test 2.0, Roche, Branchburg, NJ;
with a lower detection limit of 100 IU/mL), HCV-speciﬁc antibodies (Abbott HCV EIA 2.0, Abbott, Princeton, NJ), and
HCV-speciﬁc T-cell responses were the day of exposure (n = 21
subjects) and week 1 (n = 22), week 2 (n = 49), week 4 (n = 66),
week 6 (n = 67), week 12–13 (n = 67), and week 25–26 (n = 53)
thereafter. Because some of the healthcare workers visited
slightly before or after the planned study time points, the
average time after exposure was calculated for the cohort for
each study time point. Samples from 13 healthcare workers
were tested with T-cell proliferation assays at week 0 and week
26, and samples from 14 healthcare workers were tested
with interferon-gamma (IFN-γ) enzyme-linked immunospot
(ELISPOT) assays at week 0 and week 25. Because there were
no signiﬁcant differences in the strength of the responses at
these 2 time points (Wilcoxon signed rank test), the week 25–
26 time point was used as the baseline for all healthcare
workers in this study.
Proliferation Assay

Proliferation Assay
Peripheral blood mononuclear cells (PBMCs) were separated
from citrate dextrose–anticoagulated blood and stimulated with
1 μg/mL HCV core, NS3, NS4, NS5A, or NS5B proteins; buffer
control (Mikrogen, Germany); and 1 μg/mL phytohemagglutinin (PHA-M; Invitrogen, Carlsbad, CA) as positive control as
described [11]. Tetanus toxoid (5 μg/mL; Chiron Corporation,
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However, none of these prospective studies assessed HCVspeciﬁc T-cell responses. T-cell responses are relevant because
the small percentage of patients who clear acute HCV infection
spontaneously, approximately 20%, mount vigorous HCVspeciﬁc T-cell responses, and T-cell–mediated immune
memory may protect humans [7] and chimpanzees [8, 9] upon
reexposure. In contrast, antibodies are not required for HCV
clearance as shown in hypogammaglobulinemic patients [10],
and antibody titers decrease signiﬁcantly within 10–20 years
after HCV clearance [11].
HCV-speciﬁc T-cell responses were also described in crosssectional studies on seronegative subjects such as injection drug
users [4, 12–15], family members of HCV-infected patients
[16–18], and healthcare workers [19] who test negative for
HCV RNA despite an increased risk of HCV exposure. Based
on these studies, it has often been suggested that years of lowdose HCV exposure may prime and maintain HCV-speciﬁc T
cells that protect against systemic infection [13, 14, 17]. However,
due to unknown exposure dates and lack of longitudinal
immune response analysis, in particular with early time points
after exposure, it cannot be excluded that the studied subjects
had resolved a regular acute HCV infection in the distant past
and subsequently lost HCV-speciﬁc antibodies [11].
In the current study, 72 healthcare workers were enrolled
upon documented HCV exposure and studied frequently, that
is, up to 5 times in the ﬁrst 6 weeks and at 3 months and 6
months after exposure. In contrast to a previous study that was
smaller and had less frequent and later sampling [20], we found
a pattern of early transient T-cell responses that was associated
with the transmission risk score. Our results support the hypothesis that HCV-speciﬁc T cells are more sensitive indicators

Emeryville, CA) was used as additional control for 36 subjects.
The cutoff for a signiﬁcant proliferative response was deﬁned as
stimulation index (SI; counts of incorporated 3H-thymidine in
the presence of antigen/counts in the absence of antigen)
greater than the mean SI plus 2 standard deviations (SDs) of
proliferation assays performed with PBMCs from 29 antiHCV–negative blood donors from the NIH Department of
Transfusion Medicine.

PBMCs were stimulated with pools of overlapping pentadecamer peptides spanning the HCV core, NS3, NS4A, and NS4B
sequence (1 μg/mL of each peptide), 1 μg/mL PHA as positive
control, or dimethyl sulfoxide (DMSO) as negative control as
described [22]. To test whether other immune responses
changed due to HCV exposure, tetanus toxoid and a pool of 15
Epstein-Barr viruses (EBVs) were used as additional controls
for 18 subjects. A subject was classiﬁed as T-cell responder if
there was a signiﬁcant response to at least 2 HCV antigens in
the proliferation assay (core, NS3, NS4, NS5A, or NS5B) or the
ELISPOT assay (core, NS3, NS4A, or NS4B), respectively. A
subject was classiﬁed as T-cell nonresponder if all assays were
negative when tested on at least 3 of the 5 time points after exposure. If tested on fewer than 3 time points, the subject was excluded (n = 10). The cutoff for a signiﬁcant HCV-speciﬁc
response (spots with antigen minus spots without antigen) was
deﬁned as greater than the mean plus 2 SDs of the response of
29 anti-HCV–negative blood donors and more than 2-fold
above the DMSO background.

Timing of HCV-Speciﬁc T-Cell Responses After Low-Dose HCV
Exposure

As shown in Figure 2, HCV-speciﬁc T-cell proliferation peaked
at week 4 (6-fold over the week 26 baseline; paired analysis,
P = .0046) and HCV-speciﬁc IFN-γ responses peaked at week 6

Statistical Analysis

Fisher exact test, χ² test, D’Agostino and Pearson omnibus normality tests, and nonparametric Wilcoxon matched-pairs tests were
performed with GraphPad Prism 5.0a (GraphPad Software,
La Jolla, CA). Two-sided P values < .05 were considered signiﬁcant.
Funding Source

The funding source did not inﬂuence the collection, analysis,
and interpretation of data; the writing of the report; or the decision to submit the paper for publication.
RESULTS
HCV-Speciﬁc T-Cell Responses in Exposed Healthcare
Workers in the Absence of Systemic Viremia and
Seroconversion

Seventy-two healthcare workers were studied prospectively after
documented accidental exposure to HCV-contaminated blood
via needlestick or cut (n = 54, 75%) or via a splash of blood onto
skin or mucosa (n = 18, 25%). All study participants tested negative for HCV RNA at the sensitivity level of 100 IU/mL of the
standard clinical assay and for HCV antibodies on all study
dates. To determine whether HCV-speciﬁc T cells were induced
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Figure 1. Prevalence of T-cell responses in groups of healthcare
workers with different types of exposure. Percentage of healthcare
workers with hepatitis C virus (HCV)-speciﬁc proliferative T-cell responses
(n = 63). Cutaneous/mucosal exposure is deﬁned as a splash of HCVinfected blood on skin or eye/mouth mucosa. Needlestick exposures are
classiﬁed based on the transmission risk as low, medium, and high. Statistical analysis: χ² test to compare all groups and Fisher exact test to
compare subgroups.
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IFN-γ Enzyme-Linked Immunospot

despite the absence of detectable systemic viremia, we tested
serial PBMC samples in proliferation and IFN-γ ELISPOT
assays. Thirty of 63 tested healthcare workers (48%) demonstrated HCV-speciﬁc T-cell proliferation and 26 of 62 tested healthcare workers (42%) demonstrated HCV-speciﬁc IFN-γ responses
against at least 2 HCV antigens. Fifty-three exposed healthcare
workers were tested using both assays. Using both 13/53 (24%)
showed both HCV-speciﬁc proliferative and IFN-γ T-cell responses, 21/53 (40%) showed neither, and 19/53 (36%) showed
either proliferative or IFN-γ T-cell responses. Calculation of the
needlestick transmission risk score for those exposed via needlestick did not reveal any signiﬁcant difference among the groups.
The prevalence of proliferative T-cell responses differed among
groups with different types of exposure (P = .0093 comparing all
groups, Figure 1). Furthermore, among healthcare workers with
needlestick injuries, the prevalence of proliferative T-cell responses was signiﬁcantly higher in those with a high-risk needlestick (transmission risk score of 4–5) than in those with a
low-risk needlestick (score 0–1; 73% vs 15%, P = .011; Figure 1).
In contrast, there was no difference in the prevalence of IFN-γ
ELISPOT responses among these subgroups (data not shown).

after exposure (32-fold over baseline; P = .0062). Week 25–26 was
used as a baseline because more samples were available for week
25–26 than for week 0 and because the week 25–26 response did
not differ from the week 0 response for those tested at both time
points. Changes in T-cell responsiveness were HCV speciﬁc
because there was no signiﬁcant change in the magnitude of
T-cell responses against tetanus toxoid and EBV peptides.
Breadth of the HCV-Speciﬁc T-Cell Response

To analyze the breadth of the T-cell response, we determined
the number of HCV antigens recognized by each healthcare

worker and the frequency with which each antigen was recognized by the entire healthcare worker cohort (Figure 3). The
majority of the healthcare workers recognized multiple HCV
antigens in both proliferation (Figure 3A) and ELISPOT assays
(Figure 3B), but only 7/63 (11%) subjects responded to all antigens in the proliferation assay and 5/62 (8%) subjects responded to all antigens in the ELISPOT assay (data not shown). Four
of the 5 HCV proteins (core, NS3, NS5A, and NS5B) were recognized with almost equal frequency (20%–26%) in the proliferation assays, while NS4 was recognized somewhat less
frequently (12%; Figure 3C). Likewise, the core-, NS3-, NS4A-,
and NS4B-speciﬁc peptide pools were recognized with almost
equal frequency (23%–28%) in the IFN-γ ELISPOT assays
(Figure 3D). Overall, about three quarters of the HCV-speciﬁc
T-cell responses of exposed healthcare workers targeted nonstructural HCV antigens even though these are not present as
protein components of the HCV particle but encoded by viral
RNA inside. However, relative to their respective amino acid
length, all nonstructural antigens were less immunogenic than
the core antigen, which is a structural component of the HCV
particle.
Occupational Exposure to HCV
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Figure 2. Magnitude and kinetics of hepatitis C virus (HCV)-speciﬁc
T-cell responses after HCV exposure. Fold-change in the magnitude of
HCV-speciﬁc T-cell proliferation (A) and interferon-gamma (IFN-γ) enzymelinked immunospot (ELISPOT) responses (B). Mean ± standard error of data
from all subjects with a signiﬁcant T-cell response are shown (n = 22 in
panel A, n = 21 in panel B). For each healthcare worker, the sum of responses to all individual HCV antigens is normalized to the week 25–26
response. Week 25–26 was used as baseline because more samples were
available for week 25–26 than for week 0 and because the week 25–26
response did not differ from the week 0 response for those tested with Tcell proliferation assays (n = 13) and IFN-γ ELISPOT assays (n = 14) at both
time points. Because some healthcare workers did not visit on the exact
date of the planned visit, the average time after exposure is indicated for
the cohort at each study time point. Statistical analysis: Nonparametric
Wilcoxon matched pairs tests comparing the magnitude of the HCV-speciﬁc
T-cell response of each healthcare worker at different time points after
exposure ( paired analysis).

Figure 3. Breadth and speciﬁcity of the hepatitis C virus (HCV)-speciﬁc
T-cell response. Number of HCV antigens recognized by individual patients
in proliferation (A) and interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISPOT) assays (B). Prevalence of HCV-speciﬁc T-cell responses
against structural and nonstructural HCV antigens in proliferation assays
(C) and IFN-γ ELISPOT assays (D). Only signiﬁcant responses, that is, above
the cutoff deﬁned in the Material and Methods section, were evaluated.

DISCUSSION
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This study demonstrates that T-cell responses are more sensitive indicators of low-dose HCV exposure than antibodies and
that these responses can be the sole evidence for HCV exposure
if viremia is below the detection limit of the standard clinical
assay. T-cell responses against nonstructural HCV proteins
provide evidence that transient and/or anatomically contained
HCV infection must have occurred despite undetectable systemic viremia. This is because nonstructural HCV proteins are
not part of the HCV particle and are expressed only when a
virus has infected a cell and initiated RNA translation and potentially replication. Moreover, the infectious source in this
current study is blood from chronic HCV patients with systemic viremia, which implies that viral RNA (with the capacity to
directly prime T cells) as well as viral proteins (that would
allow T-cell induction via cross-priming) are likely transmitted.
A brief and transient period of HCV replication below the
detection limit of the standard virological assay used at the
NIH may indeed be sufﬁcient for T-cell induction because the
magnitude and kinetics of the T-cell response to a given pathogen are determined upon exposure and do not require antigen
persistence [23]. In contrast, the induction of antibodies, in
particular neutralizing antibodies in HCV infection, depends
on the continued presence of high antigen levels [11]. This is
consistent with data from other infections where low-level exposure to HIV or woodchuck hepatitis virus (WHV) leads to
the appearance of virus-speciﬁc T-cell response in the absence
of virus-speciﬁc antibodies [24, 25]. Indeed, low-level viral
DNA was detected in the WHV study [25]. While low or transient HCV RNA may be detectable in the plasma samples of
the exposed subjects in our study, with more sensitive assays it
might be possible that HCV is solely detectable in the PBMC or
the liver compartment, as has been reported for cases with
occult HCV infection [26–28]. Thus, healthcare workers who
do not seroconvert should not be classiﬁed as nonexposed controls in HCV surveillance studies.
How do the observed T-cell responses in this exposed
cohort, which tested HCV RNA nonreactive at the assay sensitivity of 100 IU/mL, differ from those of acutely infected patients with high levels of systemic viremia who later clear
HCV or progress to chronic infection? Notably, HCV-speciﬁc
T-cell proliferation peaked at week 4 and IFN-γ production
peaked at week 6 in our study. This is 1 to 2 months earlier
than described for acute HCV infection, where the virus frequently outpaces the adaptive immune response [29, 30]. A potential explanation is a boost of preexisting HCV-speciﬁc T-cell
memory induced by previous exposures in the distant past.
This is possible because most of the studied subjects had been
healthcare workers for many years when this study was conducted. However, while HCV-speciﬁc T-cell proliferation was
slightly increased at week 0 (2.44-fold over the week 26 baseline

level), this did not reach signiﬁcance and was not associated
with increased IFN-γ ELISPOT responses. Moreover, HCVspeciﬁc T-cell responses were transient and returned to levels
below the mean plus 2 SDs of the response of healthy unexposed controls in all but 2 healthcare workers within 12 weeks
after exposure. They therefore differ from the strong memory
responses that remain readily detectable in proliferation and
IFN-γ ELISPOT assays for decades after recovery and resolution of HCV [11]. We favor the explanation that the rapidity of
the T-cell response was due to the very small amount of transmitted virus; this is supported by an inverse correlation
between the speed of appearance of HCV-speciﬁc T cells and
the amount of transmitted virus that was recently demonstrated
in a nonhuman primate model [3].
A second difference between our exposed cohort with undetectable viremia and a typical acutely infected cohort with
high-level viremia and increased alanin aminotransferase
values [22] is the strength of the T-cell response. Both proliferative T-cell responses and IFN-γ production were weaker in the
current study than in a previous cohort with acute hepatitis
that we studied using the same techniques [22]. Unfortunately,
the weakness of the T-cell response rendered it technically impossible to study responses at the single peptide level and to use
tetramers to further characterize the phenotype of the induced
T cells. It is therefore an important conﬁrmation that we observed similar kinetics and antigen speciﬁcity in proliferation
and ELISPOT assays and when using HCV proteins and
peptide pools.
The sole difference between proliferation assay and ELISPOT
assay results in our study is the observation that proliferative Tcell responses, but not IFN-γ ELISPOT responses, differentiated
between high-risk and low-risk needlestick injuries. This is
consistent with reports in HIV-infected individuals that proliferation rather than ex vivo IFN-γ production of HIV-speciﬁc T
cells is associated with control of viremia [31]. Likewise, we reported previously that T-cell proliferation rather than IFN-γ
production peaked at time points of transient control of
viremia in acute HCV infection [22, 24].
In conclusion, the results demonstrate that HCV-speciﬁc Tcell responses, as measured in particular with in vitro proliferation assays, are more sensitive biomarkers of HCV exposure
than antibodies. Whether these T-cell responses reﬂect protective immunity or whether they are downstream events of protective innate immune responses or abortive replication of
defective viral genomes requires further studies in suitable
models.

Potential conﬂicts of interest. All other authors report no potential
conﬂicts.
All authors have submitted the ICMJE Form for Disclosure of Potential
Conﬂicts of Interest. Conﬂicts that the editors consider relevant to the
content of the manuscript have been disclosed.
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